limits of treatment of health-care associated infections ...impact of definitive therapy with...
TRANSCRIPT
![Page 1: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/1.jpg)
Limits of treatment of health-care associated infections
Nicola PetrosilloNational Institute for Infectious Diseases
“L. Spallanzani” - Rome
![Page 2: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/2.jpg)
Species BSI 86-97
BSI 06-07
VAP 86-97
VAP 06-07
UTI 86-97
UTI 06-07
S.aureus 13.4 14.5 17.4 24.4 Nd 2.2CoNS 33.5 34.1 - 1.3 Nd 2.5Enterococci 12.8 12.1 - - 14.1 9.6P.aeruginosa Nd 3.1 17.4 16.3 11.2 10.0Enterobacteria 5.2 3.9 20.7 18 19.2 11.8Acinetobacter - 2.2 - 8.4 - 1.2Candida spp 5.8 10.0 - 2.4 14.4 14.5Other
Idron AI et al. Inf Control Hospital Epidemiol 2008; 29:11
![Page 3: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/3.jpg)
Agents of Healthcare associated Infections
•Staphylococcus aureus the most flexible pathogen and its resistance prophile
•Acinetobacter spp: surprisingly MDR or PDR
•An old never forgotten opportunistic pathogen: P. aeruginosa
•Worrisome news in Enterobacteriaceae
![Page 4: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/4.jpg)
Major emerging resistance issues in Gram‐negative pathogens
Pathogens Resistance issues Impact
Enterobacteriaceae
FQsExp.-spectrum cephems MDR (ESC/FQ/AG)Carbapenems
++++++++
+/ (++)*
P. aeruginosaAll anti-pseudomonas agents (ex. colistin) MDR/PDR/XDR
++
AcinetobacterAll anti-acinetobacter agents (MDR/PDR/XDR)Colistin R clone are emerging
++
* In some epidemiological settings 1) Giske CG et al AAC 2008; 52:813, 2) Pitout JDD et alLancet Inf Dis 2008; 8:159, 3) Moellering RC et al AJIC 2007Nov., 4) Mendes RE et al CID 2008; 46:1324, 5) Li J et al CID 2007;45: 594, 6) Cornaglia G. et al IJAA 2007; 29: 380, 7) Endimiani et al 2007; 51:2211Courtesy by Prof. Stefani
![Page 5: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/5.jpg)
Limits due to the lack of new
(and efficient) antimicrobials
![Page 6: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/6.jpg)
Cooper MA, Shlaes D. Nature 2011;472:32.
![Page 7: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/7.jpg)
Spellberg B et al, Clin Infect Dis 2008; 46:155-64
![Page 8: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/8.jpg)
1999 Oxazolidinones1962 Quinolones
1962 Streptogramins
1958 Glycopeptides
1952 Macrolides
1950 Aminoglycosides
1949 Chloramphenicol
1949 Tetracyclines
1940 β-Lactams
1936 Sulfonamides
1930 1940 1950 1960 1970 1980 1990 2000
Development of New Antibiotics Over Time
2000 Glycylcyclines
2003 Lipopeptides
![Page 9: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/9.jpg)
![Page 10: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/10.jpg)
![Page 11: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/11.jpg)
![Page 12: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/12.jpg)
Emergence of serine carbapenemase KPC-3 among Klebsiella pneumoniae in hospitals of Rome, Italy
Carattoli A et al. ICAAC 2011, P-C2-660, Chicago
•101 patients with suspected CPKP were enrolled; KP-producing blaKPC-3 was identified in 95 cases (94%); 3 patients carried strains producing blaVIM (all from the same hospital) and 5 were infected with strains negative to the Hodge Test but positive to the blaCTX-M-15 ESBL gene associated to porin defects.
INTER-HOSPITAL SPRED OF KPC-PRODUCING STRAINS:
•We observed the inter-hospital spread of two major clones producing KPC-3: ST512 and ST258.
•KPC-3 was also identified in clones ST646 (new ST), ST650 (new ST) and ST14
•The blaVIM gene was identified in clones ST646, ST647 and ST648 (three new STs).
•4/5 strains negative for KPC but showing ESBL and porin defects belonged to ST37 the other was assigned to the new ST649.
![Page 13: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/13.jpg)
Nordmann P et al. Emerg Infect Dis 2011; 17
![Page 14: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/14.jpg)
Nordmann P et al. Emerg Infect Dis 2011; 17
![Page 15: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/15.jpg)
Nordmann P et al. Emerg Infect Dis 2011; 17
![Page 16: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/16.jpg)
Walsh TR et al. Lancet Infect Dis 2011; 11:355-62
![Page 17: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/17.jpg)
Patel G et al. Expert Rev Anti Infect Ther 2011; 9: 555–570
![Page 18: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/18.jpg)
Limits of the available agents:
is the combination therapy the solution?
![Page 19: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/19.jpg)
Is combination antimicrobial treatment beneficial for serious bacterial infections?
• Most relevant analyses have not shown better results with combination antimicrobial treatment compared with broad-spectrum beta-lactam monotherapy– Paul M. et al. BMJ 2004;328:668 (beta-lactam
monotherapy versus beta-lactam –aminoglycoside combination therapy in immunocompetent patients)
– Cunha BA. Crit Care 2006;10:141 (ventilator associated pneumonia: monotherapy is optimal if chosen wisely)
• A specific population that deserves further study on this issue is patients with P. aeruginosa bacteremia
![Page 20: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/20.jpg)
Bassetti M et al. Curr Med Chem 2008; 15:517-22
![Page 21: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/21.jpg)
Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for
Pseudomonas aeruginosa bacteremia
Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G,Falagas ME
PLoS One 2011
Table 3. Multivariable analysis of factors possibly associated with treatment success
Factor OR 95% Conf. Interval p-value
Very long (>2 months) hospitalization
0.73 0.01-0.95 0.046
Hospitalization in ICU prior to bacteremia
0.67 0.09-4.78 0.69
Age-adjusted Charlson comorbidity index
1.02 0.76-1.38 0.88
HIV 0.59 0.08-4.23 0.60
Combination therapy 3.30 0.63-17.22 0.15
54 BSI
20 mono
34 combo
![Page 22: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/22.jpg)
Petrosillo N et al. Expert Review Anti Infect Ther 2010;8:289-32
![Page 23: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/23.jpg)
Int J Antimicrob Agents 2010;35:39-44.
• Rifampicin acts by inhibiting DNA dependent RNA polymerase in bacterial cells, thus preventing transcription to RNA and subsequent translation to proteins.
•Rifampicin is an antibiotic that does not effectively penetrate through the outer membrane of Gram-negative bacteria alone.
•However, if associated with antibiotics that permeabilise the outer membrane of Gram-negative bacteria (such as colistin), rifampicin may also be effective for Gram-negative bacteria.
![Page 24: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/24.jpg)
•A literature review was performed of clinical studies reporting the use of rifampicin in the treatment of MDR Gram-negative bacterial infections.
•Nineteen studies were found, including only one randomised controlled study.
•Data in the literature on combined therapeutic regimens with rifampicin are limited and refer mostly to uncontrolled studies.
•Therefore, the real clinical benefit of using rifampicin-containing therapies for the treatment of Gram-negative multiresistant bacteria in terms of clinical outcome and survival rates still needs to be assessed.
Int J Antimicrob Agents 2010;35:39-44.
![Page 25: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/25.jpg)
•Time-kill assays confirmed the synergistic interaction between tigecycline and levofloxacin, amikacin, imipenem and colistin for 5 of 7 selected isolates.
•No antagonism was confirmed by time-kill assays.
![Page 26: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/26.jpg)
Table 2. Antibiotic resistance phenotype and checkerboard results obtained with DOR in
combination with five antibiotics in 24 A. baumannii isolates. Isolates are ranked in decreasing
order of resistance.
1Isolates showing an intermediate level of susceptibility were classified as resistant.
Abbreviations: R-, resistant to; S-, sensitive to; DOR, doripenem; TIG, tigecycline; COL, colistin;
AMK, amikacin; SAM, ampicillin/sulbactam; RIF, rifampicin; Sy, synergy; In, indifference. The
synergistic activities are shaded in grey.
DOR in combination with Study code (Hospital) Antibiotic-resistance phenotype1 DOR TIG COL AMK SAM RIF
5 (A) R-TIG-AMK-SAM-RIF (S-COL) R Sy In In In In 50 (C) R- COL-AMK-SAM-RIF (S-TIG) R In In In In In 80 (D) R-TIG-AMK-SAM-RIF (S-COL) R Sy In In In In 183 (D) R-TIG-AMK-SAM-RIF (S-COL) R Sy Sy In In In ACICU R-TIG-AMK-SAM-RIF (S-COL) R In Sy Sy Sy In 11 (B) R-TIG-AMK-RIF (S-SAM-COL) R Sy In In In In 71 (C) R-TIG-AMK-SAM (S-COL-RIF) R Sy In In In In 75 (C) R-TIG-AMK-RIF (S-COL-SAM-) S In In In In In 105 (C) R-AMK-SAM-RIF (S-TIG-COL) R In In In In In 108 (C) R-AMK-SAM-RIF (S-TIG-COL) R In Sy Sy In In 137 (L) R-AMK-SAM-RIF (S-TIG-COL) R In Sy In In In 138 (M) R-AMK-SAM-RIF (S-TIG-COL) R Sy Sy In Sy In 188 (D) R-AMK-SAM-RIF (S-TIG-COL) R In Sy Sy In In 198 (D) R-TIG-AMK-RIF (S-COL-SAM) R Sy Sy In In In 226 (P) R-TIG-SAM-RIF (S-COL-AMK) R Sy In In In In 82 (D) R-TIG-RIF (S-COL-AMK-SAM) S In In In In In 110 (I) R-SAM-RIF (S-TIG-COL-AMK) R In In In In In 133 (L) R-AMK-RIF (S-TIG-COL-SAM) S In In In In In 174 (P) R-SAM-RIF (S-TIG-COL-AMK) R In Sy Sy In Sy RUH 875 R-SAM-RIF (S-TIG-COL-AMK) S In In In In In 123 (L) R-SAM (S-TIG-COL-AMK-RIF) R In In In In In RUH 134 R-SAM (S-TIG-COL-AMK-RIF) S In In In In In 122 (L) (S-TIG-COL-AMK-SAM-RIF) S In In In In In 215 (P) (S-TIG-COL-AMK-SAM-RIF) S In In In In In
National Institute for infectious Disease “Lazzaro Spallanzani”,
Via Portuense 292, 00149, Rome, Italy.Phone: 39 0655170432
Fax: 39 0655170486
E-736 In Vitro Activity of Doripenem in Combination with Various Antimicrobials Against Multidrug Resistant Acinetobacter baumannii: Possible Options for the Treatment of Complicated Infections.
Principe L et al. ICAAC 2011
![Page 27: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/27.jpg)
Daikos GL et al. Anticrob Agents Chemother 2009; 53: 1868-73
•Prospective observational studies of cases of VIM-producing K pneumoniae bacteremia
• 49 pts treated with appropriate empirical therapythose who were treated with 2 active drugs (carbapenem plus either colistin or aminoglicoside) had higher (but not significant) survival.
![Page 28: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/28.jpg)
Lee J et al. J Clin Microbiol 2009; 47:1611-2
•None of those treated both with polymyxin and carbapenem showed changes in the MIC for either polymyxin B or carbapenem.
•Combination might be useful in the preventing the development of resistance during therapy
![Page 29: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/29.jpg)
Kontopidou F et al. Clin Microbiol Infect 2011; 17: E9–E11
![Page 30: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/30.jpg)
Carbapenemases
Courtesy by Prof. Stefani
![Page 31: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/31.jpg)
Limits of treatment for MDR Gram negative agents:
How can we overcome it?
![Page 32: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/32.jpg)
Ambrose PG et al. Diagn Microb Infect Dis 2009; 63:38-42
![Page 33: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/33.jpg)
Ambrose PG et al. Diagn Microb Infect Dis 2009; 63:38-42
•Probabilities of clinical response and PK-PD target attainment were poorly correlated at MIC values >0.25 mg/L.
•For instance, the median probability of clinical success was 0.76, whereas the probability of PK-PD target attainment was 0.27 at an MIC value of 1 mg/L, suggesting that the probability of PK-PD target attainment metrics underestimates the clinical performance of tigecycline at higher MIC values.
![Page 34: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/34.jpg)
![Page 35: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/35.jpg)
Daikos GL et al. Clin Microbiol Infect 2011; 17: 1135–1141
![Page 36: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/36.jpg)
Daikos GL et al. Clin Microbiol Infect 2011; 17: 1135–1141
![Page 37: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/37.jpg)
Roberts JA et al. J Antimicrob Chemother 2009; 64:142-50
![Page 38: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/38.jpg)
Keel RA et al. Int J Antimicrob Agents 2011; 37174-85
![Page 39: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/39.jpg)
Pournaras S et al. Int J Antimicrob Agents 2011; 37:244-47
![Page 40: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/40.jpg)
Pournaras S et al.Int J Antimicrob Agents 2011; 37:244-47
![Page 41: Limits of treatment of health-care associated infections ...Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas](https://reader034.vdocuments.us/reader034/viewer/2022042201/5ea10f84dc36c346965c3822/html5/thumbnails/41.jpg)
Nebulized and intravenous colistin in experimental pneumonia causedby P. aeruginosa Lu Q et al Intensive Care Med (2010) 36:1147–1155
Lung bacterial burden after 24 h of colistin administration
In the aerosol group, median peak lung tissue concen-tration of colistin was 2.8 mcg g-1 (25–75% IQR: 0.8- 13.7 )In the intravenous group, colistin could not be detected in any of the analyzed lung segments.